A forced expiratory flow at 25-75% value <65% of predicted should be considered abnormal: a real-world, cross-sectional study. 2012

Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
Istituto di Ricovero e Cura a Carattere Scientifico-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy. gio.cip@libero.it

Forced expiratory volume in 1 second (FEV1) is considered an important parameter for asthma diagnosis and follow-up. However, it has been proposed that forced expiratory flow at 25-75% (FEF(25-75)) could be more sensitive than FEV1 to detect slight airways obstruction. In this regard, a cutoff FEF(25-75) value has been recently established in a group of asthmatic children: FEF(25-75) < 65% of predicted has been considered impaired. However, the considered population was specifically selected. Therefore, the aim of the present study was to confirm an FEF(25-75) cutoff value in a large cohort of asthmatic children. Seven hundred allergic children (493 male subjects; median age, 11 years) with controlled and partly controlled asthma were evaluated by performing spirometry and skin-prick tests. Three hundred thirteen (44.7%) patients had FEF(25-75%) values of <65% of predicted. Two predictors were significantly associated with impaired FEF(25-75) values: (i) sensitization to perennial allergens (adjusted odds ratio [OR(Adj)], 3.4) and (ii) FEV(1) ≤ 86% of predicted (OR(Adj), 3.8). This study, conducted in real life, could suggest that FEF(25-75) value of <65% of predicted may be considered abnormal.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008297 Male Males
D008450 Maximal Midexpiratory Flow Rate Measurement of rate of airflow over the middle half of a FORCED VITAL CAPACITY determination (from the 25 percent level to the 75 percent level). Common abbreviations are MMFR and FEF 25%-75%. Forced Expiratory Flow 025-075 Percent,FEF 25-75 Percent,Flow Rate, Maximal Midexpiratory,MMFR,25-75 Percent, FEF,25-75 Percents, FEF,FEF 25 75 Percent,FEF 25-75 Percents,Forced Expiratory Flow 025 075 Percent,Percent, FEF 25-75,Percents, FEF 25-75
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females

Related Publications

Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
July 2014, BMJ open,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
January 1980, Bulletin europeen de physiopathologie respiratoire,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
February 2011, The Journal of allergy and clinical immunology,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
October 2021, Biomedicines,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
January 1986, Allergologia et immunopathologia,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
April 2022, Chronic obstructive pulmonary diseases (Miami, Fla.),
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
October 2020, ERJ open research,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
October 2022, BMJ open respiratory research,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
February 2018, Tanaffos,
Giorgio Ciprandi, and Michele Capasso, and Mariangela Tosca, and Carmelo Salpietro, and Annamaria Salpietro, and Gianluigi Marseglia, and Mario La Rosa
January 2011, Allergy and asthma proceedings,
Copied contents to your clipboard!